PE20091201A1 - AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) - Google Patents

AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)

Info

Publication number
PE20091201A1
PE20091201A1 PE2008001640A PE2008001640A PE20091201A1 PE 20091201 A1 PE20091201 A1 PE 20091201A1 PE 2008001640 A PE2008001640 A PE 2008001640A PE 2008001640 A PE2008001640 A PE 2008001640A PE 20091201 A1 PE20091201 A1 PE 20091201A1
Authority
PE
Peru
Prior art keywords
alkyl
btk
tyrosine kinase
methyl
inhibitors
Prior art date
Application number
PE2008001640A
Other languages
English (en)
Spanish (es)
Inventor
Peter A Blomgren
Kevin S Currie
Jeffrey E Kropf
Seung H Lee
Zhongdong Zhao
Scott A Mitchell
Jianjun Xu
Aaron C Schmitt
Pavel E Zhichkin
Douglas G Stafford
Original Assignee
Cgi Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cgi Pharmaceuticals Inc filed Critical Cgi Pharmaceuticals Inc
Publication of PE20091201A1 publication Critical patent/PE20091201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
PE2008001640A 2007-09-20 2008-09-19 AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk) PE20091201A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97399507P 2007-09-20 2007-09-20
US5077708P 2008-05-06 2008-05-06

Publications (1)

Publication Number Publication Date
PE20091201A1 true PE20091201A1 (es) 2009-09-13

Family

ID=40377565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001640A PE20091201A1 (es) 2007-09-20 2008-09-19 AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)

Country Status (14)

Country Link
US (2) US7884108B2 (enExample)
EP (1) EP2188267B1 (enExample)
JP (1) JP5485894B2 (enExample)
KR (1) KR20100072032A (enExample)
CN (1) CN101861307B (enExample)
AR (1) AR068503A1 (enExample)
AU (1) AU2008302099B2 (enExample)
BR (1) BRPI0817130A2 (enExample)
CA (1) CA2700443A1 (enExample)
CL (1) CL2008002793A1 (enExample)
PE (1) PE20091201A1 (enExample)
RU (1) RU2470923C2 (enExample)
TW (1) TWI423966B (enExample)
WO (1) WO2009039397A2 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080839A1 (es) * 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
US7838523B2 (en) * 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
ES2554615T3 (es) * 2008-05-06 2015-12-22 Gilead Connecticut, Inc. Amidas sustituidas, método de preparación y utilización como inhibidores de Btk
CN103408533B (zh) 2008-06-24 2015-08-26 霍夫曼-拉罗奇有限公司 新型取代的吡啶-2-酮和哒嗪-3-酮
CA2728683C (en) 2008-07-02 2017-05-02 F.Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
BR112012028530A2 (pt) * 2010-05-07 2017-12-19 Genentech Inc composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
ES2561277T3 (es) 2010-09-01 2016-02-25 Gilead Connecticut, Inc. Piridinonas/pirazinonas, procedimiento de preparación y procedimiento de utilización de las mismas
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005285A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.
RU2622391C2 (ru) 2011-11-03 2017-06-15 Ф. Хоффманн-Ля Рош Аг Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона
MX2014005289A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de piperazina alquilados.
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP3366685A1 (en) 2012-01-09 2018-08-29 X-Chem, Inc. Tryptoline derivatives having kinase inhibitory activity and uses thereof
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2014108820A1 (en) * 2013-01-08 2014-07-17 Aurigene Discovery Technologies Limited Substituted 2-pyrazinone derivatives as kinase inhibitors
WO2014125410A1 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited N-substituted heterocyclic derivatives as kinase inhibitors
PH12020550201A1 (en) * 2013-03-15 2024-01-15 Deciphera Pharmaceuticals Llc N-acyl-n-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
BR112015025260B1 (pt) 2013-04-25 2021-11-03 Beigene, Ltd Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
BR112015031835B1 (pt) * 2013-06-19 2022-12-13 Som Innovation Biotech, S.L Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético
KR101815360B1 (ko) 2013-07-03 2018-01-04 에프. 호프만-라 로슈 아게 헤테로아릴 피리돈 및 아자-피리돈 아마이드 화합물
WO2015017460A1 (en) 2013-07-30 2015-02-05 Gilead Connecticut, Inc. Polymorph of syk inhibitors
US9918939B2 (en) 2013-07-30 2018-03-20 Gilead Connecticut, Inc. Formulation of Syk inhibitors
ES2927567T3 (es) 2013-09-13 2022-11-08 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
SMT202000273T1 (it) * 2013-10-18 2020-07-08 Celgene Quanticel Research Inc Inibitori di bromodomini
EP2876124B1 (de) 2013-11-20 2019-01-09 Uhde Inventa-Fischer GmbH Verfahren sowie vorrichtung zur herstellung einer kristallisierbaren polymilchsäuremischung sowie polymilchsäuremischung
CN105793251B (zh) 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
CA2932609A1 (en) 2013-12-05 2015-06-11 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015170266A1 (en) 2014-05-07 2015-11-12 Lupin Limited Substituted pyrimidine compounds as btk inhibitors
SI3160956T1 (sl) 2014-06-27 2020-11-30 Celgene Quanticel Research, Inc. Inhibitorji lizin-specifične demetilaze-1
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
PL3164380T3 (pl) * 2014-07-03 2022-04-04 Celgene Quanticel Research, Inc. Inhibitory lizyno-specyficznej demetylazy-1
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3377488T3 (da) 2015-11-19 2022-10-03 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
SG10202005790VA (en) 2015-12-22 2020-07-29 Incyte Corp Heterocyclic compounds as immunomodulators
CN107033069B (zh) * 2016-02-04 2022-03-04 中国科学院合肥物质科学研究院 一种新型布鲁顿酪氨酸激酶不可逆抑制剂
ES3022188T3 (en) 2016-02-29 2025-05-28 Hoffmann La Roche Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
HRP20200728T1 (hr) 2016-04-15 2020-07-24 Abbvie Inc. Inhibitori bromodomene
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
MA45116A (fr) 2016-05-26 2021-06-02 Incyte Corp Composés hétérocycliques comme immunomodulateurs
BR112018076534A2 (pt) * 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
CN109475536B (zh) 2016-07-05 2022-05-27 百济神州有限公司 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG11201901141WA (en) 2016-08-16 2019-03-28 Beigene Ltd Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CA3034326A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
BR112019005337A2 (pt) 2016-09-19 2019-08-27 Mei Pharma Inc terapia combinada
CA3042297A1 (en) * 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
EP3558985B1 (en) 2016-12-22 2022-09-07 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MD3558990T2 (ro) 2016-12-22 2023-02-28 Incyte Corp Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
WO2018124281A1 (ja) * 2016-12-28 2018-07-05 富山化学工業株式会社 外用組成物
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
EP3602058A1 (en) 2017-03-24 2020-02-05 H. Hoffnabb-La Roche Ag Methods of treating autoimmune and inflammatory diseases
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
JP6986624B2 (ja) 2017-08-25 2021-12-22 ギリアード サイエンシーズ， インコーポレイテッド Ｓｙｋ阻害剤の多形体
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
CA3085457C (en) 2018-01-29 2023-05-23 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
HRP20230090T1 (hr) 2018-03-30 2023-03-17 Incyte Corporation Heterociklički spojevi kao imunomodulatori
PT3790877T (pt) 2018-05-11 2023-05-10 Incyte Corp Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1
MX2021010131A (es) 2019-02-22 2021-11-18 Kronos Bio Inc Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
TWI856111B (zh) 2019-06-10 2024-09-21 瑞士商百濟神州瑞士有限責任公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
AR119624A1 (es) 2019-08-09 2021-12-29 Incyte Corp Sales de un inhibidor de pd-1 / pd-l1
MX2022003578A (es) 2019-09-30 2022-05-30 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores.
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
CN112812113B (zh) * 2019-11-15 2022-09-20 杭州和正医药有限公司 免疫调节化合物、组合物及其应用
CN114380841B (zh) * 2020-10-19 2025-12-30 南京正大天晴制药有限公司 作为akt抑制剂的三环喹唑啉或二氢喹唑啉化合物
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
AU2006223409B2 (en) * 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
PE20080839A1 (es) * 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法

Also Published As

Publication number Publication date
US20090082330A1 (en) 2009-03-26
AU2008302099A1 (en) 2009-03-26
TW200914446A (en) 2009-04-01
JP2010540452A (ja) 2010-12-24
US20110059944A1 (en) 2011-03-10
WO2009039397A2 (en) 2009-03-26
US7884108B2 (en) 2011-02-08
EP2188267A2 (en) 2010-05-26
CL2008002793A1 (es) 2009-09-04
CN101861307A (zh) 2010-10-13
KR20100072032A (ko) 2010-06-29
CA2700443A1 (en) 2009-03-26
RU2010115574A (ru) 2011-10-27
BRPI0817130A2 (pt) 2015-03-31
CN101861307B (zh) 2013-05-01
WO2009039397A3 (en) 2009-05-22
RU2470923C2 (ru) 2012-12-27
TWI423966B (zh) 2014-01-21
JP5485894B2 (ja) 2014-05-07
US8247550B2 (en) 2012-08-21
EP2188267B1 (en) 2016-08-03
AR068503A1 (es) 2009-11-18
AU2008302099B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
NZ593030A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
PE20090641A1 (es) Amidas heterociclicas
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
PE20090547A1 (es) DERIVADOS DE PIRAZINONA COMO INHIBIDORES DE p38 QUINASA
PE20080828A1 (es) Compuestos y composiciones como inhibidores de la quinasa proteica
PE20141120A1 (es) Compuestos heterociclicos
PE20120008A1 (es) Derivados de fenoxi bencenosulfonamida
PE20141681A1 (es) Inhibidores de btk
UY31463A1 (es) Inhibidores de péptido desformilasa
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20081353A1 (es) Compuestos del inhibidor de fosfoinositida 3-cinasa
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
PE20120655A1 (es) Derivados de triazolopiridina como inhibidores de proteinas cinasas activadas por mitogeno p38 (map)

Legal Events

Date Code Title Description
FD Application declared void or lapsed